Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Radius Health Inc (NASDAQ:RDUS)

27.45
Delayed Data
As of Nov 22
 0.00 / 0.00%
Today’s Change
24.66
Today|||52-Week Range
55.30
-27.82%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

Radius Health, Inc. engages in the discovery and development of therapeutics for the treatment of osteoporosis, oncology, and endocrine diseases. The firm's lead product, abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.

Contact Information

Radius Health, Inc.
950 Winter Street
Waltham Massachusetts 02451
P:(617) 551-4000
Investor Relations:

Employees

Shareholders

Mutual fund holders61.76%
Other institutional52.77%
Individual stakeholders26.65%

Top Executives

Jesper HøilandPresident, Chief Executive Officer& Director
Jose CarmonaCFO, Treasurer, Principal Accounting Officer & SVP
Gary HattersleyChief Scientific Officer
Lorraine A. FitzpatrickChief Medical Officer
Brent Hatzis-SchochSenior Vice President & General Counsel